an Entity references as follows:
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.